New developments in angiogenesis: a major mechanism therapy

Cancer Journal From Scientific American

4, 209-17

Citation Report

#	Article	IF	Citations
1	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. Blood, 1999, 94, 4143-4155.	0.6	259
2	Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. European Journal of Clinical Investigation, 1999, 29, 793-801.	1.7	62
3	Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathology and Oncology Research, 2000, 6, 163-174.	0.9	39
4	The role of angiogenesis in rheumatoid arthritis: recent developments. Annals of the Rheumatic Diseases, 2000, 59, 65i-71.	0.5	91
5	Thalomid?? (Thalidomide) Capsules. Drug Safety, 2001, 24, 87-117.	1.4	75
6	Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia, 2001, 15, 1165-1170.	3.3	43
7	Taxanes and Capecitabine in Combination: Rationale and Clinical Results. Clinical Breast Cancer, 2002, 2, 287-293.	1.1	18
8	Inhibitors of the vascular endothelial growth factor receptor. Hematology/Oncology Clinics of North America, 2002, 16, 1173-1187.	0.9	24
9	Molecular targets as therapeutic strategies in the management of breast cancer. Seminars in Radiation Oncology, 2002, 12, 341-351.	1.0	9
10	Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. International Journal of Cancer, 2002, 98, 14-18.	2.3	117
11	Angiogenesis as a target in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2003, 62, 60ii-67.	0.5	139
12	Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews, 2004, 56, 1649-1659.	6.6	1,799
13	A Phase II Trial of Docetaxel Plus Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 761-767.	0.6	11
14	Mechanochemistry and Nanoscience. , 2008, , 1-102.		10
15	Vitreous Levels of Stromal Cellâ€“Derived Factor 1 and Vascular Endothelial Growth Factor in Patients with Retinopathy of Prematurity. Ophthalmology, 2008, 115, 1065-1070.e1.	2.5	137
16	Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 57-64.	0.8	619
17	Cancer, chitosan nanoparticles and catalytic nucleic acids. Journal of Pharmacy and Pharmacology, 2010, 61, 3-12.	1.2	60
18	Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opinion on Drug Delivery, 2010, 7, 927-942.	2.4	179

#	Article	IF	Citations
19	Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 485-495.	0.5	53
20	Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy. Theranostics, 2012, 2, 3-44.	4.6	727
21	Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews, 2012, 64, 206-212.	6.6	660
22	MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma. Cancer Research, 2013, 73, 844-854.	0.4	78
23	A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. European Journal of Pharmaceutical Sciences, 2013, 48, 416-427.	1.9	640
24	Nanocarriers for Diagnosis and Targeting of Breast Cancer. BioMed Research International, 2013, 2013, 1-10.	0.9	70
25	Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15999-16004.	3.3	50
26	Design of Nanoparticle-Based Carriers for Targeted Drug Delivery. Journal of Nanomaterials, 2016, 2016, 1-15.	1.5	177
27	Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 269-286.	1.7	95
28	Nanotechnology for the treatment of melanoma skin cancer. Progress in Biomaterials, 2017, 6, 13-26.	1.8	78
29	Implementation of nanoparticles in therapeutic radiation oncology. Journal of Nanoparticle Research, 2017, 19, 1.	0.8	6
30	Paramagnetic Gadolinium Complexes. SpringerBriefs in Applied Sciences and Technology, 2017, , 23-53.	0.2	0
31	Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications. Archives of Pharmacal Research, 2018, 41, 111-129.	2.7	46
32	Evaluation of the Biological Behavior of a Gold Nanocore-Encapsulated Human Serum Albumin Nanoparticle (Au@HSANP) in a CT-26 Tumor/Ascites Mouse Model after Intravenous/Intraperitoneal Administration. International Journal of Molecular Sciences, 2019, 20, 217.	1.8	16
33	Stealth Properties of Nanoparticles Against Cancer: Surface Modification of NPs for Passive Targeting to Human Cancer Tissue in Zebrafish Embryos. , 2019, , 99-124.		1
34	Nanotechnology in Targeted Drug Delivery and Therapeutics. , 2019, , 357-409.		17
35	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. Blood, 1999, 94, 4143-4155.	0.6	17
36	Nanotechnologies for Cancer Sensing and Treatment. , 2011, , 1-39.		0

#	Article	IF	Citations
37	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer. Journal of Clinical Medicine, 2021, 10, 5452.	1.0	7